Variable | OS | PFS | ||||
---|---|---|---|---|---|---|
HR | 95 % CI | p | HR | 95 % CI | p | |
Age > 60 years | 1.532 | 0.784–2.900 | 0.2 | 1.400 | 0.789–2.422 | 0.2 |
Female versus male | 1.153 | 0.606–2.170 | 0.7 | 1.359 | 0.787–2.342 | 0.3 |
B symptoms | 1.919 | 1.094–3.615 | 0.05 | 1.425 | 0.790–2.485 | 0.2 |
Bulky disease | 1.007 | 0.164–3.294 | 0.9 | 1.109 | 0.270–3.024 | 0.9 |
Hemoglobin < 12.0 g/dl | 1.636 | 0.862–3.072 | 0.1 | 1.858 | 1.076–3.193 | 0.03 |
Platelet < 150 × 109/l | 2.566 | 1.312–4.862 | 0.007 | 2.890 | 1.671–5.047 | <0.001 |
Extra-nodal sites > 1 | 3.043 | 1.354–6.197 | 0.009 | 2.332 | 1.104–4.470 | 0.03 |
LDH (U/L) | 6.695 | 3.001–17.77 | <0.001 | 4.510 | 2.440–8.989 | <0.001 |
Performance status > 1 | 1.788 | 0.674–3.972 | 0.2 | 2.033 | 0.885–4.089 | 0.09 |
Stage III/IV | 3.817 | 1.630–11.160 | <0.001 | 2.571 | 1.393–5.431 | 0.004 |
IPI > 2 | 4.442 | 2.342–8.459 | <0.001 | 3.734 | 2.146–6.444 | <0.001 |
Positive bone marrow | 1.670 | 0.856–3.153 | 0.1 | 1.294 | 0.709–2.271 | 0.4 |
Infused CD34 | 0.893 | 0.758–1.032 | 0.1 | 0.950 | 0.832–1.070 | 0.4 |
CR prior to APHSCT | 0.164 | 0.081–0.314 | <0.001 | 0.186 | 0.106–0.321 | <0.001 |
A-ALC ≥ 0.5 × 109/kg | 0.358 | 0.188–0.676 | 0.002 | 0.294 | 0.167–0.511 | <0.001 |
A-AMC ≥ 0.6 × 109/kg | 3.207 | 1.585–7.175 | <0.001 | 2.254 | 1.285–4.116 | 0.004 |
A-LMR ≥ 1 | 0.155 | 0.066–0.322 | <0.001 | 0.196 | 0.104–0.353 | <0.001 |
ALC-15 ≥ 0.5 cells/μl | 0.158 | 0.072–0.304 | <0.001 | 0.246 | 0.139–0.430 | <0.001 |
AMC-15 ≥ 0.5 cells/μl | 3.909 | 1.881–9.160 | <0.001 | 2.645 | 1.489–4.918 | <0.001 |
LMR-15 | 0.143 | 0.061–0.497 | <0.001 | 0.214 | 0.116–0.378 | <0.001 |
Plerixafor | 0.954 | 0.497–1.925 | 0.7 | 0.886 | 0.510–1.587 | 0.8 |